Market Forecast News: Point of Care Molecular Diagnostics Industry to Hit $7.09B by 2030
The report "Point of Care Molecular Diagnostics Market by Product & Service (Assays, Instruments, Software), Technology (RT-PCR, INAAT), Sample Type (Blood, Urine), Application (STD, HAI, Hepatitis, Cancer), and End User (Hospitals, Clinics) - Global Forecast to 2030", is projected to reach USD 7.09 billion by 2030, from USD 4.30 billion in 2025, with a CAGR of 10.5%. The growth of the point-of-care molecular diagnostics market is fueled by increasing demand for rapid and accurate testing, especially in emergency, remote, and decentralized healthcare settings. The rising incidence of infectious diseases such as respiratory infections, STDs, and gastrointestinal illnesses has amplified the need for timely diagnosis and treatment. Growing awareness of early disease detection and its impact on patient outcomes has promoted the adoption of point-of-care molecular diagnostic solutions across various healthcare environments. Additionally, increased investments in R&D are driving innovation in compact, high-performance platforms and expanding test menus, making molecular diagnostics more accessible at the point-of-care. Along with technological advancements and the global shift toward patient-centered care, these factors are substantially fueling the growth of the point-of-care molecular diagnostics market.
Browse 355 market data Tables and 55 Figures spread through 327 Pages and in-depth TOC on "Point of Care Molecular Diagnostics Market - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/point-of-care-molecular-diagnostic-market-143524127.html
In 2024, the RT-PCR segment held the largest share of the point-of-care molecular diagnostics market by technology.
The point-of-care molecular diagnostics market, by technology, is segmented into RT-PCR, INAAT, and other technologies. RT-PCR held the largest share of the market in 2024. Its extensive clinical utility, high sensitivity, and quick turnaround time have driven its widespread adoption across various healthcare environments. The integration of compact, user-friendly RT-PCR systems into decentralized locations like hospitals and emergency care units has further boosted their use. Increasing demand for rapid detection of infectious diseases continues to propel this technology’s growth. Additionally, ongoing product development focused on enhancing workflow efficiency and result accuracy is expected to maintain its market leadership in the near future.
In 2024, the hospitals segment held the largest share of the point-of-care molecular diagnostics market by end user.
The point-of-care molecular diagnostics market, by end user, is segmented into physicians’ offices/clinics, hospitals, research institutes, and other end users. In 2024, hospitals held the largest market share. This dominance is mainly driven by their high patient volumes and the need for rapid, accurate diagnostic solutions. The increasing burden of infectious diseases and the rising demand for timely clinical decisions in emergency and critical care settings have sped up the adoption of point-of-care molecular diagnostics in hospitals. These platforms enable quicker diagnosis and treatment initiation, helping to shorten hospital stays and improve patient outcomes. Additionally, hospitals are increasingly investing in decentralized testing capabilities to streamline workflows and ease pressure on centralized labs, increasing demand for point-of-care molecular diagnostics solutions.
North America is the largest market for point-of-care molecular diagnostics.
The point-of-care molecular diagnostics market is segmented into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held the largest market share. This is due to the region’s well-developed healthcare infrastructure, which features advanced diagnostic tools, specialized cancer treatment centers, and a highly trained medical workforce. These elements collectively promote the widespread adoption of point-of-care molecular diagnostics technologies and their integration into routine clinical practice, ensuring greater patient access across various healthcare settings.
The key players in this market are Danaher Corporation (US), bioMérieux (France), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), QuidelOrtho Corporation (US), Co-Diagnostics, Inc. (US), Biocartis Group NV (Belgium), SD Biosensor, INC. (South Korea), genedrive plc (UK), Binx Health, Inc. (US), Molbio Diagnostics Pvt. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuantuMDx Group Ltd. (UK), DetectaChem (US), Labsystems Diagnostics Oy (Finland), Akonni Biosystems, Inc. (US), Ubiquitome Limited (New Zealand), Credo Diagnostics Biomedical Pte. Ltd. (Singapore), OpGen, Inc. (US), Nuclein, LLC (US), Genes2Me (India), Axxin (Australia), and Huwel Lifesciences (India).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Point-of-Care Molecular Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
